Cullinan Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Cullinan Therapeutics, Inc. filed a Current Report on Form 8-K dated April 29, 2024, under Item 5.02 to report the appointment of Mary Kay Fenton as Chief Financial Officer, principal financial officer, and principal accounting officer, effective immediately. The company is a clinical-stage biotechnology company; this filing does not provide operating or period-end financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial statement metrics.
Material Changes and Executive Compensation
- Mary Kay Fenton, age 60, was appointed Chief Financial Officer effective April 29, 2024.
- Ms. Fenton most recently served as Interim Chief Executive Officer of Talaris Therapeutics and previously served as its Chief Financial Officer. Her prior experience includes roles at Vertex Pharmaceuticals, Semma Therapeutics, Achillion Pharmaceuticals, and PricewaterhouseCoopers.
- Her employment is at will, with an annual base salary of $495,000, prorated for 2024.
- She is eligible for an annual incentive bonus initially targeted at 40% of base salary.
- The company will grant an option to purchase 200,000 shares of common stock at an exercise price equal to the company’s closing stock price on the grant date. The option vests 25% on April 29, 2025, with the remainder vesting monthly over the following three years, subject to continued employment.
Severance, Change-in-Control Provisions, and Other Matters
- If terminated without cause or if Ms. Fenton resigns for good reason, she may receive nine months of base salary, a prorated annual bonus, and up to nine months of eligible COBRA premium support, subject to execution of a separation agreement and release.
- If termination without cause or resignation for good reason occurs within 12 months after a change in control, she may receive 12 months of base salary, her target bonus, and up to 12 months of eligible COBRA premium support.
- Upon a qualifying post-change-in-control termination, all unvested time-based equity awards held by Ms. Fenton would immediately vest and become exercisable.
- Ms. Fenton will enter into the company’s standard executive indemnification agreement and an employee confidentiality, assignment, nonsolicitation, and noncompetition agreement.
- The filing states that Ms. Fenton has no family relationship with the company’s directors or executive officers and that no other appointment arrangements or understandings exist.
Important Facts for Investors to Verify
- Review Exhibit 10.1, the complete employment agreement, for the precise definitions of “cause,” “good reason,” and “change in control,” along with all conditions to severance.
- Verify the option grant date, exercise price, final vesting schedule, and any applicable equity plan terms.
- Assess the potential cash, equity, and benefit costs associated with the severance and change-in-control provisions.
- Consult future periodic filings for the impact of the appointment and compensation arrangements on reported operating expenses and share-based compensation.